อีเซ็ท-10

• EZETIMIBE10.000 milligramต่อ 1 milligram

ประเภทควบคุม

ยาอันตราย

ข้อบ่งใช้

Clinical particulars Therapeutic indications Primary Hypercholesterolaemia Ezetimibe, co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as adjunctive therapy to diet foruse in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia who are not controlled with a statin alone. Ezetimibe, monotherapy is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia in whom a statin is considered inappropriate or is not tolerated. Prevention of Cardiovascular Events Ezetimibeis indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiate concomitantly with a statin. Homozygous Familial Hypercholesterolaemia (HoFH) Ezetimibe, co-administered with a statin, is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis) Homozygous Sitosterolaemia (Phytosterolaemia) Ezetimibe is indicated as adjunctive therapy to diet for use in patients with homozygous familial sitosterolaemia.

รหัส ATC

C10AX09 (ezetimibe)

ข้อมูลตามที่ขึ้นทะเบียนกับ อย. — ไม่ใช่คำแนะนำการใช้ยา ปรึกษาเภสัชกรหรือแพทย์ก่อนใช้เสมอ